Trinity biotech provides an update on the continued development of its continuous glucose monitor technology

Dublin, ireland, sept. 09, 2024 (globe newswire) -- trinity biotech plc (nasdaq: trib), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on the continued development of its glucose biosensor technology.  earlier this year trinity biotech was granted a european patent (ep3703565) for a novel method that enhances the performance of an indwelling sensor, such as a glucose biosensor. recent testing of this patented process has confirmed its effectiveness in improving the performance of trinity biotech's glucose biosensor. trinity biotech intends to use this breakthrough process to stabilise and improve the functionality of the glucose biosensor in its next generation continuous glucose monitor (cgm) technology.
TRIB Ratings Summary
TRIB Quant Ranking